Nemluvio (nemolizumab-ilto) — Point32Health
Atopic dermatitis
Initial criteria
- Documented diagnosis of moderate to severe atopic dermatitis
- Documentation the patient’s condition meets one (1) of the following: a) Body Surface Area (BSA) of at least 10%; b) Eczema Area and Severity Index (EASI) score of at least 16; c) Investigator’s Global Assessment/Physician Global Assessment (IGA/PGA) score of at least 3
- Patient age ≥ 12 years
- Prescribed by or in consultation with a dermatologist, allergist, or immunologist
- Documentation of one (1) of the following: a) Trial and failure of at least two of the listed medications from each of the following therapeutic categories (only one medication is required if only one is available for the category): i. Interleukin Antagonists: Adbry, Dupixent; ii. Janus Kinase Inhibitors: Cibinqo, Rinvoq; b) Contraindication to all the following: Adbry, Cibinqo, Dupixent, Rinvoq
Reauthorization criteria
- Documented diagnosis of moderate to severe atopic dermatitis
- Patient age ≥ 12 years
- Prescribed by or in consultation with a dermatologist, allergist, or immunologist
- Documentation the patient has experienced a therapeutic response as defined by one (1) of the following: a) Reduction in body surface area involvement relative to pretreatment baseline; b) Improvement in atopic dermatitis symptoms as evidenced by marked improvements in symptoms such as pruritus, xerosis, crusting, or lichenification; c) Reduction in the use of other topical or systemic therapies
Approval duration
initial 6 months; reauth 12 months